Rhinomed Limited (ASX:RNO)

27.0¢

right-arrow Created with Sketch. 0.015 (5.88%)
MCAP $68.52M
Last trade 15.45pm 26/11/2021 20mins delayed

Latest Announcements

19/11/2021RNORhinomed Limited
19/11/2021RNORhinomed Limited
19/11/2021RNORhinomed Limited
11/11/2021RNORhinomed Limited
03/11/2021RNORhinomed Limited
29/10/2021 Price SensitivePSRNORhinomed Limited
27/10/2021 Price SensitivePSRNORhinomed Limited
18/10/2021RNORhinomed Limited

Company Overview

Rhinomed Limited is an Australia-based medical technology company that enhancing respiration, sleep, diagnosis of upper respiratory disease, and nasal drug delivery. The Company’s products include Mute, Turbine, Pronto Sleep, and Pronto Clear. The Mute is a nasal technology that is designed to allow the user to manage the sleep by breathing more and snoring less. The Turbine is a nasal dilator designed to assist the user to breathe during aerobic exercise. Pronto Sleep, which combines the benefits of a nasal dilator, to open the nose and improve airflow, with the soothing vapors of four pure essential oils. Pronto Clear, which combines the benefits of a nasal dilator, to open the nose and improve airflow, with the ability to deliver the vapors of six pure essential oils traditionally known to clear a stuffy nose naturally. Its products, including Turbine and Mute, are sold online and through pharmacies, sleep clinics, and sports stores.

RNO in the news

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to…
Rhinomed (RNO) receives an order for one million Rhinoswabs from the Victorian…
Rhinomed (RNO) receives a purchase order from the NSW Government for its…
Rhinomed (RNO) has received a research and development (R&D) tax incentive refund…

Search Previous Announcements